Background: Recent evidence implicates malaria as a likely risk factor for the development of type 2 diabetes mellitus (T2DM) through insulin resistance. However, the nature of malaria-induced insulin resistance and its relation to parasitaemia as well as the influence of multiple episodes on insulin resistance are unknown. As a result, the current work was designed to investigate the nature, the extent of infection and effects of episodes of malaria on insulin resistance in adult Sprague-Dawley rats. Methods: One hundred and forty rats were used for the experiments. Rats were grouped into naïve, malaria only, T2DM only and comorbidity of malaria and T2DM groups. Malaria was induced by Plasmodium berghei. Serum glucose and insulin levels were assessed before, during and after P. bergheiinduced malaria. Homeostatic models assessment of insulin resistance (HOMAIR) and beta cell function (HOMAB) were computed. After the first bout of infection, animals were treated and subjected to the second episode of P. berghei infection. Results: Compared to the naïve group, levels of glucose and HOMAIR in the various treatment groups increased (P <0.05) but that of HOMAB decreased during the first episode of P. berghei infection. After treatment, only HOMAIR level was comparable across groups with glucose and HOMAB levels being highest in T2DM only and P. berghei-infected only animals respectively. A similar trend was observed in the second episode of P. berghei infection except that increased HOMAIR was observed at a much lower (P = 0.045) parasitaemia of 6.45% compared to 9.13% in the first episode. Parasitaemia correlated positively with HOMAIR (R = +0.297; P = 0.028) irrespective of episode of infection. Hypoglycemic effect of metformin was attenuated in P. berghei infection. Conclusion: P. berghei infection increased HOMAIR levels in diabetic and non-diabetic rats even at a relatively reduced parasitaemia. This observation may have implications for the evolution of T2DM in malaria-endemic regions.
INTRODUCTION
Insulin resistance which refers to the impaired sensitivity of cells to insulin action is a major risk factor for the development of type 2 diabetes mellitus (T2DM). Insulin resistance normally coexists with beta cell dysfunction and precedes the onset of full-blown T2DM. Globally, the incidence of T2DM is increasing with the sub-Saharan Africa region projected to experience the highest increase in incidence. Currently, the International Diabetes Federation (IDF) estimates that 415 million adults living with T2DM in 2015 will rise to 642 million by 2040 (1) . In respect of sub-Saharan Africa, the number of adults with the disease is expected to rise from 14.2 million in 2015 to 34.2 million by 2040 (1) . This represents an increase of 140.85% compared to the expected global increase of 54.7%. Additionally, subSaharan Africa region harbors the highest proportion of undiagnosed cases of T2DM, making the region at risk of diabetes-related complications. The gloomy prediction of increased incidence of T2DM for the sub-Saharan Africa is based on expected increased prevalence of obesity in the region. Obesity which signifies accumulation of excess fat is highly prevalent in Ghana (2, 3) and may contribute to the development of T2DM through insulin resistance. Thus, insulin resistance seems to be the link between T2DM and a number of risk factors of T2DM. Interestingly, Africa in general and the sub-Saharan region, in particular, is grappling with the menace of various communicable diseases caused by varied infectious agents. For instance, the continent bears the greatest proportion of global malaria burden in terms of morbidity and mortality (4) . In fact, malaria continues to be the number one cause of outpatient visit in Ghanaian health facilities in spite of the aggressive efforts at controlling its spread and disease burden. These observations account for the view of the double burden of disease associated with the African continent as it is faced with the burdens of both communicable and non-communicable diseases. To this end, the interaction between communicable diseases such as malaria and non-communicable counterpart, like T2DM, may pose additional challenge worth investigating. Although few studies have reported hyperinsulinemia and hypoglycemia in severe cases of malaria in animal models (5, 6) and human (7) subjects, the recognition of hypoglycemia as a critical complication of severe malaria which is more prevalent in children is not in doubt (8) . The hypoglycemia could be due to the combined effect of insulin action, increased utilization of host glucose by the malaria parasites and impaired anabolism of glucose. In semi-immune adults, mild, uncomplicated malaria is more prevalent and is associated with increased rate of gluconeogenesis (9) and raised circulating glucose levels (10) . These observations suggest that the effect of malaria on glucose metabolism may be complex.
Indeed, recent evidence in human studies seems to suggest that malaria causes insulin resistance in both children and adult (10, 11) , probably through interaction with markers of inflammation, oxidative stress and lipid metabolism (12, 13) . This observation which was made in both severe (11) and mild (10) forms of human malaria makes the likely link between malaria and T2DM unambiguous since insulin resistance is an important risk factor for the development of T2DM. However, scientific information on the nature of malaria-induced insulin resistance and its relationship with the degree of infection is virtually non-existent. Considering the burden of malaria on the African continent, the predicted incidence of T2DM and the possibility of multiple episodes of the malarial condition, the interaction between the two conditions can present a novel challenge that requires thorough investigation to avert the likely associated negative consequence. To this end, the current work was designed to assess the nature of malaria-induced insulin resistance and its relationship with infection episodes in adult Sprague-Dawley rats with or without T2DM. Also, the hypoglycemic effect of metformin was assessed.
METHODS

Animals
Healthy Sprague-Dawley rats weighing 150 ± 100 g and Plasmodium berghei NK-65 (P. berghei) were obtained from Noguchi Memorial Institute for Medical Research, University of Ghana, Legon. The rats were kept in the animal house of the Department of Biomedical Sciences, UCC, Ghana. The malaria parasites in the rat were kept alive by continuous intraperitoneal passage to healthy rats every 4 days (14) . All the animals were housed under standard laboratory conditions (21 ± 2 °C, 40 ± 5 % humidity, and 12-h light-dark cycles) and were allowed free access to food and water. The rats were housed in stainless cages (35 × 48 × 18 cm) with soft wood shavings as bedding and allowed free access to water and normal rat chow (Agricare, Kumasi, Ghana). The use of animals was in agreement with the National Institute of Health Guidelines for Care and Use of Laboratory Animals and was approved by the Department Ethical Review Committee.
Drugs and chemicals
The following drugs and chemicals were used: streptozotocin (STZ) and nicotinamide were obtained from Sigma-Aldrich, St. Louis, MO, USA, metformin HCl and artemether-Lumefantrine were obtained from Ernest Chemist, Accra, Ghana.
Experimental design, induction of type 2 diabetes mellitus and first episode of P. berghei infection
In all, one hundred and forty adult Sprague -Dawley rats were used for the study. Animals were broadly grouped into 4 groups of 35 animals per group. Group 1 animals served as the naïve group without diabetes or malaria. Group 2 animals served as the P. bergheiinfected only group with the animals in group 3 serving as the T2DM only group. Animals in group 4 were induced with both P. berghei infection and T2DM and served as the co-morbidity group. Induction of T2DM in rats was done by the method of Punitha et al. (15) . Briefly, rats were intraperitoneally administered 60 mg/kg STZ dissolved in ice cold 0.1 M citrate buffer 15 minutes after the intraperitoneal administration of nicotinamide (120 mg/kg dissolved in normal saline). After 7 days, rats showing fasting blood glucose levels of 10 mmol/L or greater were considered diabetic. Induction of T2DM occurred in groups 3 and 4 animals. Apart from fasting glucose, circulating insulin level was also assessed in all the groups of animals for computation of insulin resistance and beta cell function. Induction of P. berghei infection was achieved by inoculation of rats with 1x10 6 P. berghei parasitized red blood cells intraperitoneally. After 72 h, parasite multiplication was assessed microscopically by parasites presence in blood from the tail of infected animals. P. berghei infection was induced in groups 2 and 4 animals only. Induction of P. berghei infection was done on day 12 after initiating the induction of T2DM.
Determination of parasitaemia
Malaria parasitaemia was determined by standard microscopy. Briefly, three drops of blood collected from the tail of each infected animal was smeared onto a microscope slide to make a thick film. The smears were fixed in absolute ethanol and stained with 10% Giemsa stain and examined microscopically.
Blood glucose, insulin, insulin resistance and beta cell function determinations
Fasting blood glucose (mmol/L) and insulin level (mU/mL) were measured for computation of insulin resistance and beta cell function. Fasting blood glucose was determined by the enzymatic method using a glucometer. Insulin was measured by enzymelinked immunosorbent assay (ELISA) kit, procured from Mercodia (Uppsala, Sweden) in accordance with manufacturer's instructions. Estimation of insulin resistance and beta-cell function were in line with the homeostatic model assessment of insulin resistance (HOMAIR) and beta cell function (HOMAB) formula developed by Matthews and colleagues (16) . Although the hyperinsulinemic-euglycemic clamp is the gold standard for assessment of insulin resistance, the technique is complex, costly, invasive, prone to hypoglycemia and requires advanced expertise (17) for reliable results, hence, our choice of HOMAIR. Although HOMAIR is a surrogate marker of insulin resistance, it has been found to strongly correlate with the hyperinsulinemic-euglycemic clamp and the insulin tolerance test in rat (17, 18) . To this end, the homeostatic model can be considered a reliable method for assessment of insulin resistance and beta cell function in animal studies.
Treatment of first episode and induction of the second episode of P. berghei infection P. berghei-infected animals (groups 2 and 4 animals) were treated with 1.14 mg/kg athemeter-lumefantrine daily for five days starting on the third day after the first episode of infection. Additionally, diabetic animals (groups 3 and 4 animals) were treated with 100 mg/kg metformin starting from the same day of treatment initiation for the first episode of P. beghei infection. Animals with co-morbidity of P. berghei infection and T2DM (group 4) received both 1.14 mg/kg athemeter-lumefantrine and 100 mg/kg metformin daily. As expected, levels of blood glucose, insulin, insulin resistance and beta cell function were determined after pharmacological treatment. To assess the effect of a second episode of malaria on insulin resistance, groups 2 and 4 animals successfully treated with athemeter-lumefantrine or both athemeter-lumefantrine and metformin, where appropriate, were subjected to another bout of P. berghei infection five days post first episode treatment of P. berghei infection. Prior to the induction of the second episode of infection, parasite density was determined to ensure that animals had attained at least 85% parasite clearance (approximately 1.48% parasitaemia from the average value of 9.13%). As expected, groups 2 and 4 animals were inoculated with 1x10 6 P. berghei parasitized red blood cells. The parasite density was determined again after 72 h before initiating treatment with 1.14 mg/kg athemeter-lumefantrine for the next five days. It is important to note that diabetic animals continued to receive 100 mg/kg metformin daily before, during and after P. berghei infection. Above all, the level of blood glucose, insulin, insulin resistance and beta cell function were assessed in animals before, during and after pharmacological treatment of P. berghei infection.
Statistical Analysis
SPSS version 16 was used to analyze the data obtained and presented as a mean ± standard deviation. Mean levels of the measured indices were compared across groups by one-way analysis of variance (ANOVA) with Tukey's HSD posthoc test. Partial correlation was used to assess linear association between any pair of measured indices. A p-value < 0.05 was used to determine statistical significance.
RESULTS
Effects of the first episode of P. berghei infection on insulin resistance and beta cell function
Fasting levels of glucose and insulin were measured in animals before, during and after P. berghei infection for assessment of insulin resistance by the homeostatic model. Group 1 animals were naïve, not infected with P. berghei or T2DM and served as the control group. Compared to naïve animals, animals in the various treatment groups exhibited higher (P < 0.05) levels of glucose and HOMAIR but a lower level of HOMAB (table 1) . However, insulin level was comparable (P > 0.05) between the naive animals and those of the various treatment groups. When levels of the measured indices were compared between P. bergheiinfected only rats (group2) with their counterpart that had T2DM only or both T2DM and P. berghei infection, it was observed that rats infected with P. berghei only, exhibited lower glucose levels but a higher level of beta cell function (HOMAB). In general, HOMAIR was highest in the co-morbidity group of animals (group 4), followed by P. bergheiinfected only animals (group 2) and the T2DM only (group3) animals in that order. However, HOMAIR level was comparable (P = 0.225; table 1) between group2 and group3 animals during this phase of the study. Overall, the data point to increased insulin resistance coupled with reduced beta cell function in the first episode of P. berghei infection. Interestingly, either metformin or athemeter-lumefantrine or both had no effect on circulating levels of insulin and glucose. 
Effect of artemether-lumefantrine on P. berghei-induced insulin resistance
To study the nature of malaria-induced insulin resistance, P. berghei-infected animals (average parasitaemia 9.13%) were administered 1.14 mg/kg athemeter-lumefantrine daily for five days starting from day 3 after first-episode infection. Also, rats induced with T2DM and those co-morbid with T2DM and P. berghei infection were administered 100 mg/kg metformin. After the 5-day treatment with1.14 mg/kg athemeter-lumefantrine, average percentage parasitaemia dropped from 9.13% to 1.48% representing approximately 85% parasite clearance. As indicated in table 2, HOMAIR level declined (P = 0.069; table 2) across all the groups of animals after the 5-day treatment of P. berghei infection, suggesting that P. berghei-induced insulin resistance, was transient in nature. As expected, HOMAB level increased after the pharmacological treatment of diabetes and/or malaria although the extent of increase differed across groups (table 2). Compared to the naïve group, rats with only P. berghei infection and those with only T2DM exhibited respective higher and lower levels of HOMAB (P < 0.001; table 2) after appropriate pharmacological treatment. However, animals infected with both P. berghei and T2DM comorbidity had comparable (P = 0.493; table 2) level of HOMAB with the naïve group. Apart from animals induced with only T2DM (group 3) which showed a higher level of glucose (7.49 mmol/L versus 5.23 mmol/L; P = 0.041; table 2) than the naïve group (group1), glucose levels in all the other groups were comparable to the naïve group after the 5-day pharmacological treatment of animals with 1.14 mg/kg athemeter-lumefantrine. Insulin level was only found to be higher in animals infected with P. berghei only (group2) when compared to those induced with T2DM only (group3) (6.81 versus 3.16; P = 0.037; table 2). When the observed changes in levels of measured biomarkers during and after the 5-day 1.14 mg/kg athemeter-lumefantrine treatment of animals were expressed in percentage terms, animals infected with the co-morbidity of both P. berghei and T2DM exhibited the highest (P < 0.001; figure 1) percentage increase in HOMAB but decrease in glucose and HOMAIR levels, followed by those with only T2DM and animals with only P. berghei infection in that order. The extent of change observed for glucose, HOMAIR and HOMAB was extremely higher than the observed changes in insulin level (figure 1). It is interesting to note that an extremely high increase in HOMAB, signifying hyper-secretory activity of the beta cells, was necessary to induce a relatively marginal reduction in HOMAIR levels in the various groups of animals (figure 1). Key: Group 1 = Naïve rats; Group2 = rats infected with P. berghei only; Group3 = rats with T2DM only; Group4 = rats with both P. berghei and T2DM co-morbidity; T2DM = type 2 diabetes mellitus; HOMAIR = homeostatic model assessment of insulin resistance; HOMAB = homeostatic model assessment of beta cell function; * = significant p-value; ANOVA = analysis of variance. Insulin and glucose levels are presented in mU/ml and mmol/L respectively. 
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Figure 1: Changes in levels of measured indices during and after the first episode of P. berghei infection.
Group1 = Naïve rats; Group2 = rats infected with P. berghei only; Group3 = rats with T2DM only; Group4 = rats with both P. berghei and T2DM co-morbidity; T2DM = type 2 diabetes mellitus; HOMAIR = homeostatic model assessment of insulin resistance; HOMAB = homeostatic model assessment of beta cell function; *% Paras = Percentage parasitaemia before athemeter-lumefantrine treatment. Apart from parasitaemia, all the other values signify percentage reduction (-) or increment after 5-day pharmacological treatment.
Effects of the second episode of P. berghei infection on insulin resistance
To investigate how the second episode of P. berghei infection would impact on insulin resistance, groups 2 and 4 animals were re-inoculated with 1x10 6 P. berghei parasitized red blood cells, five days after completion of episode 1 treatment with 1.14 mg/kg athemeter-lumefantrine. Diabetic animals were, however, continued on the 100 mg/kg metformin treatment during the 5-day resting period to keep their circulating glucose level within the expected range. Prior to the re-induction of P. berghei infection, parasitaemia was determined as described earlier to ascertain the sustenance of parasite clearance within the 85% target. Levels of the various indices were also determined and found to have remained unchanged from levels obtained after the 5-day 1.14 mg/kg athemeter-lumefantrine treatment of the first episode of P. berghei infection. As expected, after day 3 post re-infection, parasitaemia was observed to have risen to averagely 6.45% with levels of glucose, HOMAIR and HOMAB differing significantly (P < 0.001; table 3) from the naïve group in a trend similar to that found in the first episode. Expectedly, HOMAIR was significantly (P = 0.046; table 3; figure 2) higher in the co-morbidity group of animals (group4) than the P. berghei-infected only animals (group 2). Interestingly, the rise in glucose and HOMAIR levels, as well as the decline in HOMAB levels observed during the second episode of P. berghei infection, was similar to the levels in the first episode. Rats with comorbidity of both T2DM and P. berghei infection exhibited a higher percentage increase in glucose and HOMAIR but decrease in HOMAB in the second episode of P. berghei infection (figure 2). Similar to our observation in episode 1, treatment of animals with 1.14 mg/kg athemeter-lumefantrine for five days, resulted in reduced levels of glucose and HOMAIR (Figure 3) . Indeed, the trend of change in levels of the various indices was similar in the two episodes of P. berghei infection (Figure 3) . A third bout of P. berghei infection could not be induced as animals appeared to have developed adequate resistance to the infection. 
Effects of metformin on glucose level during P. berghei infection
To assess the effectiveness of metformin in reducing circulating glucose level in diabetic animals during P. berghei infection, we monitored glucose levels of animals in groups 3 (T2DM only) and 4 (T2DM and P. berghei infection). As indicated in figure 4 , after five days of treatment with 100 mg/kg metformin or both 1.14 mg/kg athemeter-lumefantrine and 100 mg/kg metformin based on the underlying disease condition, glucose level was lower in animals with only T2DM compared with those with comorbidity of T2DM and P. berghei infection (glucose level 5.6 mmol/l versus 8.7 mmol/l; P = 0.037, figure 4) , suggesting a possible attenuation of metformin's ability to reduce blood glucose level in the presence of P. berghei infection.
Association of insulin resistance with parasitaemia
We investigated the relationship between parasitaemia, glucose, insulin, HOMAIR and HOMAB using Pearson partial correlational test that controlled for diabetic status, pharmacological treatment and episodes of P. berghei infection. As indicated in table 4, parasitaemia correlated positively with HOMAIR (R = +0.297; P = 0.028) only. As expected, glucose correlated positively with insulin and HOMAIR but negatively with HOMAB. Moreover, HOMAB correlated negatively with HOMAIR (R = -0.348; P = 0.009; table 4). 
DISCUSSION
The use of animal models to study human diseases has contributed to improved understanding of the pathogenesis and management of a number of human diseases. In the current study, the nature of insulin resistance caused by malaria was investigated in type 2 diabetic and non-diabetic Sprague-Dawley rats, as a model for human malaria in type 2 diabetes patients and their non-diabetic counterpart. Compared with naïve uninfected animals, animals infected with P. berghei exhibited higher levels of plasma glucose and HOMAIR but a lower level of HOMAB in line with observations in human studies (2, 3) but at variance with other studies in mice and rat which reported a lower level of glucose during P. berghei infection (19, 20, 21) . The elevated glucose level has been ascribed to increased gluconeogenesis (22) and reduced glucose utilization by uninfected red blood cells (23) , suggesting that circulating glucose level during Plasmodial infection depends on the degree of infection. However, the difference between the current study and the earlier ones (19, 20, 21) could stem from differences in the type of the investigated malaria cases. Whereas the observation of reduced glucose level due to P. berghei infection by previous studies (19, 20, 21) mirrored the situation in severe cases of malaria, the current study is centered on mild malaria cases as normally observed in adult semi-immune human subjects. Insulin is an important hormone whose activity is critical to the circulating level of blood glucose. Although several animal and human studies conducted decades ago (23, 24, 25) have reported hypoglycemia due to malaria parasite-induced hyperinsulinemia, the current report did not find any significant change in insulin level before and during P. berghei infection irrespective of infection episode. The variation in observation between the current report and the earlier ones (23, 24, 25) could be due to differences in the extent of infection, animal model as well as the Plasmodium species used in the investigations. The hypoglycemia in the presence of hyperinsulinemia clearly indicates that the cells were responsive to insulin-mediated glucose uptake (23, 24, 25) , contrary to the findings of the current study where insulin level was comparable, but glucose level was higher in P. berghei-infected rats compared to the naïve uninfected animals. This observation which occurred in the first episode of P. berghei infection points to a possible insulin resistance and is further buttressed by the observed increased HOMAIR but decreased HOMAB levels in animals with P. berghei infection only or co-morbidity of P. berghei infection and T2DM compared with naïve animals. Undeniably, a combination of insulin resistance and impaired beta cell function remain the fundamental cause of T2DM development. To this end, any condition that is capable of inducing insulin resistance and beta cell dysfunction should increase the potential for development of T2DM (1) . As expected, successful pharmacological treatment of P. berghei infection with 1.14 mg/kg athemeterlumefantrine resulted in reduced glucose and HOMAIR levels but increased HOMAB level pointing to the transient nature of the malaria-induced insulin resistance in support of the hypothesis that malaria is an acute infectious condition (25) .When animals were re-infected with P. berghei for the second episode, a similar trend of increased glucose and HOMAIR but decreased, HOMAB was observed with subsequent improvement after pharmacological treatment. However, a relatively low level of parasitaemia (6.45%) in the second episode of P. berghei infection compared with the first episode (9.13%) raised HOMAIR to a level similar to that observed in the first episode. This finding which mimics the immunological response of cells to a second or multiple encounters of same or similar antigen, suggests that some residual insulin resistance might be established after the first episode of P. berghei infection which contributed to the heightened HOMAIR during the second episode even at a muchreduced parasitaemia. Additionally, the finding points to a likely increased trend of HOMAIR at muchreduced parasitaemia envisaged for multiple bouts of malaria which is feasible in humans but could not be induced in the current study due to the resistance of rats to subsequent P. berghei infection. This notwithstanding, our finding is a clear proof of principle that successive episodes of malaria could prime affected cells to insulin resistance and thus increase the risk of the affected to the development of T2DM. This prediction is plausible considering the sharp increased HOMAB after the clearance of P. berghei from infected cells. Thus, with multiple episodes of malaria, cycles of suppression and hyperrecovery of the secretory function of beta cells is expected. This expected recovery may be unsustainable and attenuated with time, due, possibly to, hyperglycemia-induced apoptosis of beta cells (26) which could contribute immensely to the development T2DM. Hence, our finding provides the first evidence that a second episode of P. berghei infection at a relatively reduced parasitaemia, induced insulin resistance to an extent similar to the first episode and may pre-dispose infected animals to the development of T2DM through insulin resistance. However, further studies may be necessary to confirm this finding, especially in humans, so as to devise rational strategies to curb the growing incidence of T2DM in malariaendemic regions, especially, when diabetes patients are known to be more susceptible to malaria than nondiabetic controls (27) . Interestingly, the hypoglycemic effect of metformin during P. berghei infection appeared to be attenuated in the current work as the sharp decline in glucose level induced by metformin in animals with T2DM only was not observed in those with comorbidity of T2DM and P. berghei infection. Also, the mean glucose level attained by animals after six days of metformin administration was lower in the T2DM only group compared with their comorbid counterpart. This finding, which requires further studies for confirmation and possible elucidation of the underlying mechanism is crucial in the light of a recent review that suggests that insulin resistance and hyperglycemia augment the risk of the adverse cardiovascular outcome in humans (28) .
CONCLUSION
P. berghei infection increased HOMAIR level in adult Sprague-Dawley rats even at a relatively reduced parasitaemia. This finding has implication for the evolution of T2DM in malaria-endemic regions. Further research is needed in both humans and animal studies for better understanding of the phenomenon.
